{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T18:16:07Z","timestamp":1781374567473,"version":"3.54.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T00:00:00Z","timestamp":1600819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T00:00:00Z","timestamp":1600819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Paraneoplastic cerebellar degeneration (PCD) is a devastating paraneoplastic syndrome that occasionally occurs in patients with Hodgkin lymphoma (HL). Anti-Ma2 is a well-characterized onconeuronal antibody and one of the causes of PCD. There has been only one previous report of anti-Ma2-associated paraneoplastic syndrome as a complication of HL. Here we present a rare case of anti-Ma2-associated PCD in a patient with nodular lymphocyte-predominant HL (NLPHL).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 77-year-old man with a 3-month history of gait instability and a 2-month history of oscillopsia was referred to our hospital for further investigation. On examination, his cognition was normal. He had nystagmus in all directions of gaze; specifically, he had horizontal and rotatory nystagmus in the primary position, downbeat nystagmus after right, left, and up gaze, and upbeat nystagmus after down gaze. Although his limb ataxia was mild, his trunk ataxia was so pronounced that he was unable to walk without support. We strongly suspected paraneoplastic syndrome and tested for neuronal autoantibodies. The anti-Ma2 antibody was strongly positive in the blood and cerebrospinal fluid but other antineuronal autoantibodies were negative. Computed tomography showed an enlarged lymph node in the right axilla but no masses. Biopsy confirmed a diagnosis of NLPHL. The NLPHL cells stained with anti-Ma-2 antibody in the cytoplasm, suggesting these abnormal cells contained protein that was cross-reactive with Ma-2.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>To the best of our knowledge, this is the first case of anti-Ma2-associated PCD in a patient with NLPHL that was confirmed using immunostaining of the lymph node tissue with anti-Ma2 antibody. Our case confirms an association between anti-Ma2-associated PCD and NLPHL.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12883-020-01929-4","type":"journal-article","created":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T12:03:02Z","timestamp":1600862582000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Anti-Ma-associated paraneoplastic cerebellar degeneration in a patient with nodular lymphocyte-predominant Hodgkin lymphoma: a case report"],"prefix":"10.1186","volume":"20","author":[{"given":"Ryoma","family":"Inui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenki","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimitsu","family":"Shimomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michi","family":"Kawamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,23]]},"reference":[{"key":"1929_CR1","unstructured":"Brunberg JA, Expert panel on neurologic imaging. Ataxia. AJNR Am J Neuroradiol 2008;29:1420\u20131422."},{"issue":"Pt 6","key":"1929_CR2","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1093\/brain\/awg133","volume":"126","author":"S Shams\u2019ili","year":"2003","unstructured":"Shams\u2019ili S, Grefkens J, de Leeuw B, van den Bent M, Hooijkaas H, van der Holt B, et al. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain. 2003;126(Pt 6):1409\u201318.","journal-title":"Brain."},{"key":"1929_CR3","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s00415-009-5431-9","volume":"257","author":"F Graus","year":"2010","unstructured":"Graus F, Saiz A, Dalmau J. Antibodies and neuronal autoimmune disorders of the CNS. J Neurol. 2010;257:509\u201317.","journal-title":"J Neurol"},{"key":"1929_CR4","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1136\/jnnp.2003.034447","volume":"75","author":"F Graus","year":"2004","unstructured":"Graus F, Delattre JY, Antoine JC, Dalmau J, Giometto B, Grisold W, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004;75:1135\u201340.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1929_CR5","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1097\/WCO.0b013e328347b307","volume":"24","author":"J Panzer","year":"2011","unstructured":"Panzer J, Dalmau J. Movement disorders in paraneoplastic and autoimmune disease. Curr Opin Neurol. 2011;24:346\u201353.","journal-title":"Curr Opin Neurol"},{"key":"1929_CR6","first-page":"669","volume":"23","author":"ML Mauermann","year":"2017","unstructured":"Mauermann ML. Neurologic complications of lymphoma, leukemia, and paraproteinemias. Continuum (Minneap Minn). 2017;23:669\u201390.","journal-title":"Continuum (Minneap Minn)"},{"key":"1929_CR7","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1182\/blood-2014-03-537506","volume":"123","author":"F Graus","year":"2014","unstructured":"Graus F, Ari\u00f1o H, Dalmau J. Paraneoplastic neurological syndromes in Hodgkin and non-Hodgkin lymphomas. Blood. 2014;123:3230\u20138.","journal-title":"Blood."},{"key":"1929_CR8","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1212\/01.WNL.0000041495.87539.98","volume":"60","author":"F Bernal","year":"2003","unstructured":"Bernal F, Shams\u2019ili S, Rojas I, Sanchez-Valle R, Saiz A, Dalmau J, et al. Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin\u2019s disease. Neurology. 2003;60:230\u20134.","journal-title":"Neurology."},{"key":"1929_CR9","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1001\/archneurol.2010.51","volume":"67","author":"R Marignier","year":"2010","unstructured":"Marignier R, Chenevier F, Rogemond V, Sillevis Smitt P, Renoux C, Cavillon G, et al. Metabotropic glutamate receptor type 1 autoantibody-associated cerebellitis: a primary autoimmune disease? Arch Neurol. 2010;67:627\u201330.","journal-title":"Arch Neurol"},{"key":"1929_CR10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1056\/NEJM200001063420104","volume":"342","author":"P Sillevis Smitt","year":"2000","unstructured":"Sillevis Smitt P, Kinoshita A, De Leeuw B, Moll W, Coesmans M, Jaarsma D, et al. Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor. N Engl J Med. 2000;342:21\u20137.","journal-title":"N Engl J Med"},{"issue":"Pt 8","key":"1929_CR11","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1093\/brain\/awh203","volume":"127","author":"J Dalmau","year":"2004","unstructured":"Dalmau J, Graus F, Villarejo A, Posner JB, Blumenthal D, Thiessen B, et al. Clinical analysis of anti-Ma2-associated encephalitis. Brain. 2004;127(Pt 8):1831\u201344.","journal-title":"Brain."},{"key":"1929_CR12","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1017\/cjn.2017.227","volume":"44","author":"P Rizek","year":"2017","unstructured":"Rizek P, Kumar N, Jog MS. Anti-Ma2-associated encephalitis secondary to Hodgkin\u2019s lymphoma. Can J Neurol Sci. 2017;44:752\u20133.","journal-title":"Can J Neurol Sci"},{"key":"1929_CR13","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/ncpneuro0426","volume":"3","author":"SH Subramony","year":"2007","unstructured":"Subramony SH. SARA--a new clinical scale for the assessment and rating of ataxia. Nat Clin Pract Neurol. 2007;3:136\u20137.","journal-title":"Nat Clin Pract Neurol"},{"key":"1929_CR14","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s004150050350","volume":"246","author":"F Blaes","year":"1999","unstructured":"Blaes F, Strittmatter M, Merkelbach S, Jost V, Klotz M, Schimrigk K, et al. Intravenous immunoglobulins in the therapy of paraneoplastic neurological disorders. J Neurol. 1999;246:299\u2013303.","journal-title":"J Neurol"},{"key":"1929_CR15","doi-asserted-by":"crossref","unstructured":"Shams\u2019ili S, de Beukelaar J, Gratama JW, Hooijkaas H, van den Bent M, van \u2018t Veer M, et al. An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes. J Neurol 2006;253:16\u201320.","DOI":"10.1007\/s00415-005-0882-0"},{"key":"1929_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0016010","volume":"5","author":"T Cui","year":"2010","unstructured":"Cui T, Hurtig M, Elgue G, Li S-C, Veronesi G, Essaghir A, et al. Paraneoplastic antigen Ma2 autoantibodies as specific blood biomarkers for detection of early recurrence of small intestine neuroendocrine tumors. PLoS One. 2010;5:e16010.","journal-title":"PLoS One"},{"key":"1929_CR17","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1200\/JCO.2007.11.8869","volume":"26","author":"L Nogov\u00e1","year":"2008","unstructured":"Nogov\u00e1 L, Reineke T, Brillant C, Sieniawski M, R\u00fcdiger T, Josting A, et al. Lymphocyte-predominant and classical Hodgkin\u2019s lymphoma: a comprehensive analysis from the German Hodgkin study group. J Clin Oncol. 2008;26:434\u20139.","journal-title":"J Clin Oncol"},{"key":"1929_CR18","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1182\/asheducation-2017.1.324","volume":"2017","author":"DA Eichenauer","year":"2017","unstructured":"Eichenauer DA, Engert A. Nodular lymphocyte-predominant Hodgkin lymphoma: a unique disease deserving unique management. Hematol Am Soc Hematol Educ Program. 2017;2017:324\u20138.","journal-title":"Hematol Am Soc Hematol Educ Program"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-020-01929-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-020-01929-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-020-01929-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T23:26:15Z","timestamp":1632353175000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-020-01929-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,23]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1929"],"URL":"https:\/\/doi.org\/10.1186\/s12883-020-01929-4","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,23]]},"assertion":[{"value":"4 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This case report did not require review by the institutional review board of our hospital. Written informed consent for treatment was obtained from the patient.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication was obtained from the patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing financial and non-financial interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"355"}}